CyFlow™ CD97 FITC
| Alternative Name: | EMR1 |
| Antibody: | Yes |
| Antigen: | CD97 |
| Application: | Flow cytometry |
| Clonality: | monoclonal |
| Clone: | MEM-180 |
| Emission Maximum: | 518 nm |
| Excitation Maximum: | 490 to 495 nm |
| Field of Interest: | Immunophenotyping |
| Format/Fluorochrome: | FITC |
| Isotype: | IgG1 |
| Laser: | Blue |
| Regulatory Status: | RUO |
| Source Species: | Mouse |
| Target Species: | Human |
| Product number: | AU837788 |
For Research Use Only
| Quantity | 100 tests |
| Volume | 2.0 mL |
| Immunogen | PHA-activated peripheral blood cells |
| Background Information | CD97 is a G-protein-coupled seven-span transmembrane adhesive receptor that is constitutively expressed on granulocytes and monocytes and rapidly upregulated on T and B cells upon activation. CD97 is produced in alternatively spliced forms and its cellular ligand is CD55 (DAF), which protects various cell types from complement-mediated damage. Interaction of CD97 on leukocytes and CD55 on vessel cells probably facilitate leukocyte activation and migration into the tissues, similarly, CD97 seems to play a role in tumor migration and invasiveness. CD97 is involved in T cell regulation and peripheral granulocyte homeostasis. |
| Usage | The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 20·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (2 ml) is sufficient for 100 tests. |
| Storage Buffer | The reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide. |
| Storage | Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze. |
| Stability | Do not use after expiration date stamped on vial label. |
| Kishimoto T, Goyert S, Kikutani H, Mason D, Miyasaka M, Moretta L, Ohno T, Okumura K, Shaw S, Springer TA, Sugamura K, Sugawara H, von dem Borne AEGK, Zola H (Eds): Leucocyte Typing VI. Garland Publishing Inc, New York. 1997; 1‑1342. < NLM ID: 9712219 > | Visser L, de Vos AF, Hamann J, Melief MJ, van Meurs M, van Lier RA, Laman JD, Hintzen RQ: Expression of the EGF‑TM7 receptor CD97 and its ligand CD55 (DAF) in multiple sclerosis. J Neuroimmunol. 2002 Nov; 132(1‑2):156‑63. < PMID: 12417446 > | Wobus M, Vogel B, Schmücking E, Hamann J, Aust G: N‑glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding. Int J Cancer. 2004 Dec 10; 112(5):815‑22. < PMID: 15386373 > | Galle J, Sittig D, Hanisch I, Wobus M, Wandel E, Loeffler M, Aust G: Individual cell‑based models of tumor‑environment interactions: Multiple effects of CD97 on tumor invasion. Am J Pathol. 2006 Nov; 169(5):1802‑11. < PMID: 17071601 > | Wang T, Tian L, Haino M, Gao JL, Lake R, Ward Y, Wang H, Siebenlist U, Murphy PM, Kelly K: Improved antibacterial host defense and altered peripheral granulocyte homeostasis in mice lacking the adhesion class G protein receptor CD97. Infect Immun. 2007 Mar; 75(3):1144‑53. < PMID: 17158902 > | Abbott RJ, Spendlove I, Roversi P, Fitzgibbon H, Knott V, Teriete P, McDonnell JM, Handford PA, Lea SM: Structural and functional characterization of a novel T cell receptor co‑regulatory protein complex, CD97‑CD55. J Biol Chem. 2007 Jul 27; 282(30):22023‑32. < PMID: 17449467 >